Research article · 2018
Conference abstract
Antipsychotic Polypharmacy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The concurrent use of two or more antipsychotics also called Antipsychotic Polypharmacy (APP) is a common practice in the treatment of psychiatric patients. In a systematic review of 147 studies published in the literature, we found a global median rate of APP of 19.6%. Differences in APP rates were noted across geographical regions. Overall, APP rates were higher in Asia and Europe compared to North America. Additionally, when looking at changes in APP rates over time in individual regions, we found that median APP rate increased in North America from 12.7% in 1980s to 17% in 2000s. Conversely, the median APP rate in Asia decreased from 55.5% in 1980s to 19.2% in 2000s. However, in spite of the common use of APP, very few randomized controlled studies have been conducted and most of the data found in the literature derives from uncontrolled naturalistic studies and chart review studies. Therefore, the evidence base to support the use of APP as standard treatment is lacking. To date, APP has been associated with a large host of factors that could be grouped into patient, illness and treatment domains. Examples of patient factors include being a male, younger age and unmarried status. In regards to illness factors, a diagnosis of Schizophrenia or Schizo affective disorder, earlier onset of illness, longer illness duration, greater illness acuity or severity and others have been associated with APP. Examples of treatment factors include involuntary treatment, hospitalization, longer inpatient stay, longer treatment duration, higher dosing, receiving quetiapine treatment and others. Besides treatment efficacy, the risk of side effects is another factor that needs to be taken into account when evaluating a new treatment strategy. To study the adverse effects associated with APP, we conducted another systematic review and found reports of a large variety of adverse effects that have been linked to APP. In general and based on mostly uncontrolled data, APP is associated with worse adverse effects when compared to antipsychotic monotherapy. Although, we found that specific combinations seem to be beneficial for the treatment of specific adverse effects such as the addition of aripiprazole to clozapine to decrease weight gain and dyslipidemia. Further data in regards to prevalence, correlates and adverse effects of APP will be discussed in the presentation. PDF HTML
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 12 Jun 2017
Antipsychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study
Conference proceeding · 25 Aug 2021
Conference Proceeding: 2nd Global Summit on Psychiatry and Psychotherapie
Conference proceeding · 24 Aug 2021
Conference Proceeding: 4th World Congress on Psychiatry and Psychological Syndromes
Conference proceeding · 13 Jul 2016
Proceedings of the 4th International Conference on Child & Family Behavioral Health-2016
More from this journal
The newest in Journal of Psychiatry.
Article · 2026
The Generational Effects of Marriage on Children: Marriage Education as a Preventive Mental Health Intervention
Article · 12 Nov 2025
From Hurt to Harm: How Childhood Trauma Shapes Cognitive Control and Decision Making in Late-Life Depression
Article · 22 Oct 2025
The Potential Importance of Electromagnetic Waves for The Treatment of Psychiatric Behavioral Disorders
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Psychiatry
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Juan A Gallego”
